13,821 Shares in Sanofi (NASDAQ:SNY) Bought by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC purchased a new position in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,821 shares of the company's stock, valued at approximately $667,000.

Other hedge funds have also recently modified their holdings of the company. Northwest Investment Counselors LLC purchased a new stake in Sanofi during the third quarter valued at approximately $29,000. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter valued at approximately $25,000. Concord Wealth Partners increased its stake in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Sanofi presently has an average rating of "Buy" and an average target price of $60.00.

Sanofi Stock Performance

Shares of NASDAQ:SNY traded up $0.33 during midday trading on Friday, reaching $54.46. The company's stock had a trading volume of 1,424,158 shares, compared to its average volume of 2,301,609. The firm has a market capitalization of $138.21 billion, a PE ratio of 21.87, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a fifty day moving average of $50.95 and a 200 day moving average of $52.53. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.